Evidence map›Paper›PMID 39840039›Full record

ArticleFrontiers in immunology2024

Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care.

María Queralt Salas, María Teresa Solano, Mónica Baile González, Marina Acera Gómez, Laura Fox, María Del Mar Pérez Artigas, Ana Santamaría, María Del Carmen Quintela González, Andrés Sánchez Salinas, Joaquina M Salmerón Camacho and 18 more

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

María Queralt SalasUnidad de Trasplante de Progenitores Hematopoyéticos, Servicio de Hematología, Hospital Clínic de Barcelona, Barcelona, Spain.
María Teresa SolanoUnidad de Trasplante de Progenitores Hematopoyéticos, Servicio de Hematología, Hospital Clínic de Barcelona, Barcelona, Spain.
Mónica Baile GonzálezServicio de Hematología, Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain.
Marina Acera GómezServicio de Hematología, Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain.
Laura FoxDepartamento de Hematología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
María Del Mar Pérez ArtigasDepartamento de Hematología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Ana SantamaríaDepartamento de Hematología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.
María Del Carmen Quintela GonzálezDepartamento de Hematología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.
Andrés Sánchez SalinasUnidad de Trasplante de Progenitores Hematopoyéticos, H.C.U. Virgen de la Arrixaca, Murcia, Spain.
Joaquina M Salmerón CamachoUnidad de Trasplante de Progenitores Hematopoyéticos, H.C.U. Virgen de la Arrixaca, Murcia, Spain.
Verónica Illana ÁlvaroDepartamento de Hematología, Hospital Universitario de la Princesa, Madrid, Spain.
Zahra Abdallahi-LefdilDepartamento de Hematología, Hospital Universitario de la Princesa, Madrid, Spain.
Javier Cornago NavascuesDepartamento de Hematología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Laura PardoDepartamento de Hematología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Sara Fernández-LuisUnidad de Trasplante de Progenitores Hematopoyéticos, Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Leddy Patricia Vega SuárezUnidad de Trasplante de Progenitores Hematopoyéticos, Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Sara VillarDepartamento de Hematología, Clínica Universidad de Navarra, Pamplona, Spain.
Patricia Beorlegui-MurilloDepartamento de Hematología, Clínica Universidad de Navarra, Pamplona, Spain.
Albert EsquirolServicio de Hematología, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain.
Isabel Izquierdo GarcíaDepartamento de Hematología, Hospital Miguel Servet, Zaragoza, Spain.
Sonia Rodríguez GonzálezInstitut Català d'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Alberto MussettiInstitut Català d'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Esperanza LavillaServicio de Hematología, Hospital Universitario Lucus Augusti, Lugo, Spain.
Javier Lopez-MarínHospital Universitario de Alicante, Alicante, Spain.
Silvia FilaferroGrupo Español de Trasplante de Progenitores Hematopoyéticos y Terapia Celular, Madrid, Spain.
Ángel CedilloGrupo Español de Trasplante de Progenitores Hematopoyéticos y Terapia Celular, Madrid, Spain.
Leyre BentoGrupo Español de Trasplante de Progenitores Hematopoyéticos y Terapia Celular, Madrid, Spain.
Anna SuredaInstitut Català d'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This multicenter prospective study sponsored by the Methods: Frailty was measured using the HCT Frailty Scale at first consultation and HCT admission in 404 adults from 15 HCT programs in Spain. Based on the results, patients were classified into fit, pre-frail and frail categories. Allo-HCT outcomes were analyzed according to the results obtained from the HCT Frailty Scale. Data was collected prospectively and all patients signed informed consent. Results: At first consultation, 102 (26.2%) patients were classified as fit, 248 (61.4%) as pre-frail, and 50 (12.4%) as frail. During the study, 62 (15.2%) patients participated in a pre-habilitation program. Among non-pre-habilitated patients (n=342), the proportion of fit patients decreased from 26.6% to 16.7%, while frail patients increased from 12.7% to 19.9%. In contrast, pre-habilitated patients (n=62) showed improvements, with fit patients increasing from 24.2% to 46.8%, and frail patients decreasing from 9.7% to 3.2%. Multivariate analysis confirmed lower OS (HR 2.52, P=0.002) and higher NRM (HR 2.69, P=0.013) in frail patients at HCT admission compared to fit ones, with a trend towards lower OS in pre-frail patients (HR 1.54, P=0.097). Conclusion: This study highlights the feasibility of incorporating the HCT Frailty Scale into clinical practice, confirms its negative impact of frailty on transplant outcomes, and suggests that frailty is dynamic and potentially reversible through pre-transplant interventions.

Indexed as

FrailtyHematopoietic Stem Cell TransplantationAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesSpainTransplantation, HomologousTreatment Outcomeallogeneic-HCTfrailty syndromeHCT Frailty Scalepre-habilitationsurvival

Identifiers

PMID39840039
PMCPMC11747426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.